Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
about
PI3K/AKT/mTOR Pathway in AngiogenesisCombined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor modelRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsMonitoring the cytoskeletal EGF response in live gastric carcinoma cellsEpidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyCytohesins/ARNO: the function in colorectal cancer cellsFocal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerAmorphous Silica Particles Relevant in Food Industry Influence Cellular Growth and Associated Signaling Pathways in Human Gastric Carcinoma CellsEGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.Confocal laser endomicroscopy and immunoendoscopy for real-time assessment of vascularization in gastrointestinal malignancies.Cembrene Diterpenoids with Ether Linkages from Sarcophyton ehrenbergi: An Anti-Proliferation and Molecular-Docking Assessment.Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase.HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines.[Translational research in head and neck cancer. Biological characteristics and general aspects].A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis.Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding.Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalkA pharmacogenomic method for individualized prediction of drug sensitivityApoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cellsErlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.Heterogeneity of KRAS Mutation Status in Rectal CancerNuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.Expression of Eag1 K+ channel and ErbBs in human pituitary adenomas: cytoskeleton arrangement patterns in cultured cellsDirect Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imagingA new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallateAnti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Modulating the tumor microenvironment to increase radiation responsiveness.The tumor microenvironment in non-small-cell lung cancerAngiogenesis-related molecular targets in esophageal cancer.
P2860
Q21129332-9E9EFABB-E860-44C0-8744-028A6B21AF20Q21133610-A00E99CF-3693-4B98-8AB6-EDC335AA9BB3Q26779221-66308BA1-2ED2-46EB-B488-D3D99B796AA1Q27318370-1C637409-501D-46DC-AB47-4516BC4668E1Q28475894-C66965FB-5729-4771-A8A6-26A3F2E49663Q28540770-A3DD9C8B-DE5C-48FB-B5C6-16AF089E88AFQ28550689-807499D2-9446-4F19-A1B7-66A836980C1FQ29249068-5ABEFEAF-AE98-4BDF-B954-3F86C4B71569Q33667547-BF636874-AB88-4C2B-9A8C-51D6460C248EQ33779199-E5DCE27A-402E-4FD9-836B-EAE4D00AC44BQ33789194-330BBB43-756A-4E29-B584-C660931EA264Q33833452-023E3848-4ED8-4296-B3F5-5F3D3D74D62FQ33918829-159A6D28-F6DE-482E-AA3A-9C526435FD7FQ33947789-4208369E-3672-4A9A-8BF8-1D3B3EF4611FQ33957227-83D822B6-1F68-4584-B167-B5C46A5760AFQ34000961-0F3CEE88-23AD-48EE-8B97-A4F60EAF0C81Q34084021-55991B40-C84E-4914-9CB4-D4FFB8C8DA32Q34089704-718ECD45-084A-44E2-BD83-E800D2C1226FQ34138796-9F50C00E-AA1A-49CC-80E1-5DEEBADA8DE2Q34654728-FE5AEDA0-153A-42B5-8CBB-F4A0E7614D30Q35176386-B9B5BA81-708D-4533-B126-19704828C859Q35480110-21CF6EB1-2A4E-42E3-90B0-D81278EDB69EQ35553145-78F694C1-6C94-42E7-AF7A-B0A5083E33FFQ35642677-7C663FB2-8AFE-4F9B-B398-08DF6BB37382Q35985611-9D69AFFB-C366-4A3B-B930-664A0193A778Q36225686-2714446D-4428-4F09-990F-82F4BAE03B59Q36371890-EDFB0BDE-0B4C-4673-B88E-B2744195CB4EQ36584340-EBE78F9A-3424-4B7F-821F-0ADF01D8FD95Q36635273-109FE647-D0AC-4AC9-9BF3-902F7D5BA3EBQ36813117-C4DD59B8-244E-4065-879A-966BC5B86A13Q36935966-7729BC76-E656-4D88-9771-926C0D7B5CE2Q37158137-96C25161-5EB4-4DEC-B2B5-EC9EFD1F5BF5Q37200453-826F9AEC-7A77-4EBC-95F8-1F8EB1716DF3Q37260992-A958CBE9-A765-4CEF-9DF8-1B5588458C45Q37277197-1F65C8B2-727C-41CC-803A-09A99F5119C0Q37299934-DA0D1FFD-DB84-4A1A-ADAE-D5CC078ED2B4Q37329842-E90D3DD0-FCD7-4E0D-983E-29F48D448115Q37613364-312D443D-CFB1-44A8-9C46-6E786798537AQ37777872-DDB02A6E-BBAD-470F-8500-B75BBA7B53D5Q37858534-C08EA099-836D-4C3A-9F4B-0EADF3954A7B
P2860
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@ast
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@en
type
label
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@ast
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@en
prefLabel
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@ast
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@en
P2860
P1433
P1476
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
@en
P2093
Amit Maity
Pinaki R Dutta
P2860
P304
P356
10.1016/J.CANLET.2007.02.006
P407
P577
2007-03-23T00:00:00Z